Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare Conference

Rhea-AI Summary

Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage gene therapy company, will present at the Cantor Virtual Global Healthcare Conference on September 15, 2020, at 1:00 pm PT. The presentation will focus on their innovative gene therapy candidate, ADVM-022, aimed at treating wet age-related macular degeneration and diabetic macular edema. Investors can access a live webcast under the Events section on the company's website, with an archived version available for 30 days post-event.

REDWOOD CITY, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the company will present at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 1:00 pm PT.

A live webcast will be accessible under Events and Presentations in the Investors section of the company’s website. The archived webcast will be available on the Adverum website following the presentation for 30 days.

About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.

Investor and Media Inquiries:

Investors:
Myesha Lacy
Adverum Biotechnologies, Inc.
mlacy@adverum.com
1-650-304-3892

Media:
Cherilyn Cecchini, M.D.
LifeSci Communications
ccecchini@lifescicomms.com
1-646-876-5196

 

FAQ

When is Adverum Biotechnologies presenting at the Cantor Virtual Global Healthcare Conference?

Adverum Biotechnologies will present on September 15, 2020, at 1:00 pm PT.

What is the focus of Adverum's presentation at the conference?

The presentation will focus on their gene therapy candidate, ADVM-022, for treating wet age-related macular degeneration and diabetic macular edema.

How can I view the Adverum presentation from the Cantor Conference?

The presentation will be available via a live webcast on Adverum's website, with an archived version accessible for 30 days after the event.

What disease areas does Adverum Biotechnologies target?

Adverum Biotechnologies targets unmet medical needs in ocular and rare diseases.